Uveal Melanoma

Study Compares Outcomes for Treatments of Uncommon Eye Cancer

Study Compares Outcomes for Treatments of Uncommon Eye Cancer

Treatment with selumetinib resulted in improved progression-free survival time and tumor response rate compared with chemotherapy, but no improvement was seen in overall survival. Furthermore, the modest improvement in clinical outcomes was accompanied by a high rate of adverse effects.

Investigators learn how gene mutations cause melanoma of the eye

By

Researchers have identified a therapeutic target for treating the most common form of eye cancer in adults.

Experimental drug selumetinib benefits patients with metastatic uveal melanoma

By

The new drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new research.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs